Who founded Affinivax?

Affinivax was founded by Richard Malley in 2014.

Who are Affinivax's investors?

Affinivax's investors include Bain Capital Life Sciences, EcoR1 Capital, Foresite Capital.

How much funding has Affinivax raised?

Affinivax has disclosed $233M raised across 2 rounds.

Where is Affinivax headquartered?

Affinivax is headquartered in Cambridge, US.

Affinivax

Cambridge, US · Founded 2014 · 3 known investors

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology. The company has been acquired by GSK.

Biotech Medical Devices

Founders & leadership

Affinivax was founded in 2014 by Richard Malley.

Richard MalleyFounder

Kamran TavangarExecutive

Steven BruggerExecutive

Board

Robert MoreBoard director

Frances HellerBoard director

George SiberBoard director

Investors · 3

Bain Capital Life SciencesBoston

EcoR1 CapitalSan Francisco

Foresite CapitalWest Hollywood

Reported raises · per SEC filings

Form D private placements

$233M disclosed across 2 rounds · 2017–2021

▶$226MraisedJan 2021 · 27 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Richard MalleyDirector
Frances HellerDirector
Steven BruggerExecutive Officer, Director
Robert MoreDirector
George SiberDirector
Steven AltschulerDirector
Andrew HackDirector

Offering amount: $226M
Amount sold: $226M
First sale: Jan 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$7MraisedJan 2018 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Richard MalleyDirector
Robert MoreDirector
Frances HellerDirector
Kamran TavangarExecutive Officer
George SiberDirector
Steven BruggerExecutive Officer, Director

Offering amount: $7M
Amount sold: $7M
First sale: Dec 2017
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Affinivax do?: Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology. The company has been acquired by GSK.
Who founded Affinivax?: Affinivax was founded by Richard Malley in 2014.
Who are Affinivax's investors?: Affinivax's investors include Bain Capital Life Sciences, EcoR1 Capital, Foresite Capital.
How much funding has Affinivax raised?: Affinivax has disclosed $233M raised across 2 rounds.
Where is Affinivax headquartered?: Affinivax is headquartered in Cambridge, US.